EG 427

R&D

Despite the multiple challenges that faced clinical trials in 2023, according to GlobalData’s Pharmaceutical Intelligence Centre, some 22,338

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.